Tenax Therapeutics Inc

Insider buying fuels short‑term optimism at Tenax Therapeutics, with executives accumulating cost‑free options that signal confidence in the PH‑HFpEF pipeline amid volatility.

Insider buy by Tenax Therapeutics’ chief medical officer signals confidence as the company heads into Phase‑3 trials for its pulmonary hypertension drug.

Insider buying by Tenax Therapeutics’ owner signals confidence ahead of Phase 3 topline data, suggesting a potential rally amid volatile pricing.

Insider Almenoff June Sherie’s zero‑price option buy on Tenax hints at confidence in its levosimendan PH‑HFPf pipeline, a potential upside amid market skepticism.

Insider option buy at Tenax Therapeutics shows executive confidence amid volatility – a bullish signal tied to the company’s clinical pipeline.